Layne Christensen (LAYN) Reports First Quarter Fiscal 2012 Earnings

MISSION WOODS, Kan., June 8, 2011 (GLOBE NEWSWIRE) — Layne Christensen Company (Nasdaq:LAYN – News), today announced net income for the first quarter ended April 30, 2011, of $13,066,000, or $0.66 per diluted share, compared to net income of $6,571,000, or $0.34 per diluted share last year.

Revenues for the three months ended April 30, 2011, increased $36,656,000, or 15.9%, to $267,371,000 compared to $230,715,000 for the same period last year. A further discussion of results of operations by division is presented below.

Cost of revenues increased $28,313,000, or 16.5%, to $200,225,000, or 74.9% of revenues, for the three months ended April 30, 2011, compared to $171,912,000, or 74.5% of revenues, for the same period last year.

Selling, general and administrative expenses increased 19.4% to $40,001,000 for the three months ended April 30, 2011, compared to $33,515,000 for the same period last year. The increase was primarily due to additional expenses of $1,234,000 from acquired operations and $2,161,000 of increased compensation costs.

Depreciation, depletion and amortization increased 6.8% to $15,082,000 for the three months ended April 30, 2011, compared to $14,125,000 for the same period last year. The increase was primarily the result of acquisitions and property additions, offset by $1,909,000 lower depletion in the Energy Division as a result of updated estimates of economically recoverable gas reserves.

Equity in earnings of affiliates increased 149.3% to $4,669,000 for the three months ended April 30, 2011, compared to $1,873,000 for the same period last year. The increase reflects the impact of an improved minerals exploration market in Latin America, primarily for gold and copper in Chile and Peru.

Interest expense decreased to $344,000 for the three months ended April 30, 2011, compared to $526,000 for the same period last year, the result of scheduled debt reductions.

Other income (expense), net for the three months ended April 30, 2011, consisted primarily of a gain of $5,052,000 on the sale of a facility in California, a gain of $996,000 on the sale of certain investment securities in Australia, and gains of $590,000 on the sale of other equipment. The facility in California was sold in anticipation of relocating existing operations to a different property.

Income tax expense of $9,671,000 (an effective rate of 41.5%) was recorded for the three months ended April 30, 2011, compared to $5,826,000 (an effective rate of 47.0%) for the same period last year. The decrease in the effective rate was primarily attributable to a lesser tax impact of certain foreign operations and foreign affiliates. The effective rate in excess of the statutory federal rate for the periods was due primarily to the impact of nondeductible expenses and the tax treatment of certain foreign operations.

Summary of Operating Segment Data

The following table summarizes financial information for the Company’s operating segments. A discussion of the results of each segment follows the table.

Water Infrastructure Division revenues increased 13.4% to $196,065,000 for the three months ended April 30, 2011, from $172,905,000 for the same period last year. The increase was primarily attributable to additional revenues of $14,905,000 from acquired and start-up operations and the remainder from improved results from our pipeline construction business.

Included in revenues for the three months ended April 30, 2011 and 2010, were $3,732,000 and $5,477,000, respectively, from our project in Afghanistan. This project contributed $3,180,000 and $3,233,000, respectively, to income before income taxes for the three months ended April 30, 2011 and 2010. Drilling operations on this project have ceased and we expect to be in the process of demobilizing our equipment over the next quarter.

Included in the results of the Water Infrastructure Division for the three months ended April 30, 2011, was a gain of $5,052,000 on the sale of a facility in Fontana, California. Exclusive of this gain, income before income taxes for the Water Infrastructure Division increased 5.6% to $9,123,000 for the three months ended April 30, 2011, compared to $8,640,000 for the same period last year. The increase was primarily attributable to $1,562,000 in earnings from acquired operations, offset by lower activity than last year in our non-acquisition related geoconstruction projects.

The backlog in the Water Infrastructure Division was $530,256,000 as of April 30, 2011, compared to $553,034,000 as of April 30, 2010.

Mineral Exploration Division revenues increased 36.8% to $62,767,000 for the three months ended April 30, 2011, from $45,878,000 for the same period last year. The increase was driven by increased activity levels across all locations.

Income before income taxes for the Mineral Exploration Division increased 100.8% to $17,246,000 for the three months ended April 30, 2011, compared to $8,587,000 for the same period last year. The increase resulted primarily from improved margins, combined with higher revenues. Equity earnings from our affiliates increased $2,670,000 to $4,543,000 compared to $1,873,000 for the same period last year.

Energy Division revenues decreased 40.7% to $5,660,000 for the three months ended April 30, 2011, compared to revenues of $9,549,000 for the same period last year. The decrease is primarily attributable to lower natural gas prices compared to last year when we had favorably priced forward sales contracts for most of the quarter.

Income before income taxes for the Energy Division decreased 61.1% to $980,000 for the three months ended April 30, 2011, compared to $2,517,000 for the same period last year. The decrease was due to the impact of lower natural gas prices and the expiration of the forward sales contracts existing last year.

Net gas production by the Energy Division for the three months ended April 30, 2011, was 1,092 MMcf, compared to 1,142 MMcf for the same period last year. The average net sales price on production for the three months ended April 30, 2011, was $3.06 per Mcf compared to $7.17 per Mcf for the same period last year. The net sales price excludes revenues generated from third party gas.

Other revenues and income before income taxes increased 20.8% to $2,879,000, and 22.2% to $303,000, respectively, for the three months ended April 30, 2011, compared to the same period last year, primarily as a result of machining and fabrication operations.

Unallocated Corporate Expenses

Corporate expenses not allocated to individual divisions, primarily included in selling, general and administrative expenses, were $9,057,000 for the three months ended April 30, 2011, compared to $7,069,000 for the same period last year. The increase was primarily due to an increase of $840,000 in consulting fees related to systems integration and merger and acquisition projects.

This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Exchange Act of 1934. Such statements may include, but are not limited to, statements of plans and objectives, statements of future economic performance and statements of assumptions underlying such statements, and statements of management’s intentions, hopes, beliefs, expectations or predictions of the future. Forward-looking statements can often be identified by the use of forward-looking terminology, such as “should,” “intended,” “continue,” “believe,” “may,” “hope,” “anticipate,” “goal,” “forecast,” “plan,” “estimate” and similar words or phrases. Such statements are based on current expectations and are subject to certain risks, uncertainties and assumptions, including but not limited to: the outcome of the ongoing internal investigation into, among other things, the legality, under the FCPA and local laws, of certain payments to agents and government officials in certain countries in Africa relating to the payment of taxes and the importing of equipment (including any government enforcement action which could arise out of the matters under review or that the matters under review may have resulted in a higher dollar amount of payments or may have a greater financial or business impact than management currently anticipates), prevailing prices for various commodities, unanticipated slowdowns in the Company’s major markets, the availability of credit, the risks and uncertainties normally incident to the construction industry and exploration for and development and production of oil and gas, the impact of competition, the effectiveness of operational changes expected to increase efficiency and productivity, worldwide economic and political conditions and foreign currency fluctuations that may affect worldwide results of operations. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially and adversely from those anticipated, estimated or projected. These forward-looking statements are made as of the date of this filing, and the Company assumes no obligation to update such forward-looking statements or to update the reasons why actual results could differ materially from those anticipated in such forward-looking statements.

Layne Christensen Company provides sophisticated services and related products for the water, mineral and energy markets.

The Layne Christensen Company logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=3466

China Armco Metals (CNAM) Provides Business Update

SAN MATEO, Calif., June 7, 2011 (GLOBE NEWSWIRE) — China Armco Metals, Inc. (NYSE Amex:CNAM) (“China Armco” or “the Company”), a distributor of imported metal ore and metal recycler with a new state of the art scrap metal recycling facility in China, today announced the preliminary unaudited operating results for the first two months of the second quarter of 2011.

In April and May of this year, China Armco sold 25,000 metric tons (MT) of recycled steel products to 3 customers. The Company has recognized approximately $14 million of net sales in its recycled steel business through the first two months of the second quarter. Approximately 80% of the tonnage sold in April and May were completed using pre-selling contracts.

In addition, the Company recorded $7.1 million of revenue in its metal ore trading business. Client activity remained solid, as reflected in the 41,000 MT of metal ores sold during the first two months of the second quarter.

“Our recycling business picked up from a seasonally slow first quarter,” said Mr. Kexuan Yao, CEO and Chairman of China Armco. “We are seeing continued interest from customers to increase the amount of recycled metals purchased. So far this year, we have signed 2 new recycling customers who agreed to our pre-selling strategy. As we increase production and make further improvements in our operational efficiencies, we expect measured improvements in our profitability.”

About China Armco Metals, Inc.

China Armco Metals, Inc. is engaged in the sale and distribution of metal ore and non-ferrous metals throughout the PRC and has entered the recycling business with the recent launch of operations of a 1-million ton per year shredder and recycler of metals located on 32 acres of land. China Armco maintains customers throughout China which includes the fastest growing steel producing mills and foundries in the PRC. Raw materials are acquired from a global group of suppliers located in diverse countries, including, but not limited to, Brazil, India, Indonesia, Ukraine and the United States. China Armco’s product lines include ferrous and non-ferrous ore, iron ore, chrome ore, nickel ore, magnesium, copper ore, manganese ore and steel billet. The recycling facility is expected to be capable of recycling one million metric tons of scrap metal per year which will position the Company as one of the 10 largest recyclers of scrap metal in China. China Armco estimates the demand for recycled metal market in China will be over 120 million metric tons in 2011. For more information about China Armco, please visit http://www.armcometals.com.

Safe Harbor Statement

In connection with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, China Armco Metals, Inc., is hereby providing cautionary statements identifying important factors that could cause our actual results to differ materially from those projected in forward-looking statements (as defined in such act). Any statements that are not historical facts and that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance (often, but not always, indicated through the use of words or phrases such as “will likely result,” “are expected to,” “will continue,” “is anticipated,” “estimated,” “intends,” “plans,” “believes” and “projects”) may be forward-looking and may involve estimates and uncertainties which could cause actual results to differ materially from those expressed in the forward-looking statements. These statements include, but are not limited to, our expectations regarding our revenues, net income, earnings and production related to our scrap metal recycling operations and the extent of government imposed blackouts and the impact on our recycling operations. In addition, any such statements are qualified in their entirety by reference to, and are accompanied by, the following key factors that have a direct bearing on our results of operations:

We caution that the factors described herein could cause actual results to differ materially from those expressed in any forward-looking statements we make and that investors should not place undue reliance on any such forward-looking statements. Further, any forward-looking statement speaks only as of the date on which such statement is made, and we undertake no obligation to update any forward-looking statement to reflect events or circumstances after the date on which such statement is made or to reflect the occurrence of anticipated or unanticipated events or circumstances. New factors emerge from time to time, and it is not possible for us to predict all of such factors. Further, we cannot assess the impact of each such factor on our results of operations or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. This press release is qualified in its entirety by our partner’s ability to complete its obligations to source various minerals and ores within acceptable specifications, demand and fluctuations in the prices of those minerals and ores, our ability to resell any sourced minerals and ores at current market prices and on favorable terms, our ability to finance the purchase price of any minerals and ores, and the cautionary statements and risk factor disclosure contained in our Securities and Exchange Commission filings, including our Annual Report on Form 10-K for the year ended December 31, 2009.

CONTACT: Investor Relations:

         HC International, Inc.
         Ted Haberfield, Executive VP
         Tel: +1-760-755-2716
         Email: thaberfield@hcinternational.net
         Web: http://www.hcinternational.net

         Company:
         US Contact:
         Oliver Hu, Business Associate
         China Armco Metals, Inc.
         Office: 650.212.7620
         Mobile: 415.794.0906
         Email: oliver@armcometals.com
         Website: www.armcometals.com

         China Contact:
         Wayne Wu:
         China Armco Metals, Inc.
         Office: 021-62375286
         Cell: 18602114846
         Email: wayne.wu@armcometals.com
         Website: www.armcometals.com

Transition Therapeutics (TTHI) to Present at the Jefferies 2011 Global Healthcare Conference

TORONTO, June 7, 2011 (GLOBE NEWSWIRE) — Transition Therapeutics Inc. (“Transition” or the “Company”) (TSX:TTH) (Nasdaq:TTHI) announced today that Dr. Tony Cruz, Chairman and Chief Executive Officer of Transition, will be presenting at the Jefferies 2011 Global Healthcare Conference on Thursday June 9, 2011 at 1:30pm Eastern Time at the Grand Hyatt Hotel in New York City.

About Transition

Transition is a biopharmaceutical company, developing novel therapeutics for disease indications with large markets. Transition’s lead product is ELND005 (AZD-103) for the treatment of Alzheimer’s disease and Transition also has an emerging pipeline of innovative preclinical and clinical drug candidates. The other drugs in the pipeline that the Company is developing are for anti-inflammatory and metabolic indications. Transition’s shares are listed on the NASDAQ under the symbol “TTHI” and the Toronto Stock Exchange under the symbol “TTH”. For additional information about the Company, please visit www.transitiontherapeutics.com.

Notice to Readers: Information contained in our press releases should be considered accurate only as of the date of the release and may be superseded by more recent information we have disclosed in later press releases, filings with the OSC, SEC or otherwise. Except for historical information, this press release may contain forward-looking statements, relating to expectations, plans or prospects for Transition, including conducting clinical trials. These statements are based upon the current expectations and beliefs of Transition’s management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include factors beyond Transition’s control and the risk factors and other cautionary statements discussed in Transition’s quarterly and annual filings with the Canadian commissions.

For further information on Transition, visit www.transitiontherapeutics.com, or contact:

CONTACT: Dr. Tony Cruz
         Chairman & Chief Executive Officer
         Transition Therapeutics Inc.
         Phone: (416) 260-7770, x.223
         tcruz@transitiontherapeutics.com

         Elie Farah
         President & Chief Financial Officer
         Transition Therapeutics Inc.
         Phone: (416) 260-7770, x.203
         efarah@transitiontherapeutics.com

Selected Value Therapeutics Exercises Right to Develop and Commercialize ENMD-2076 in China

ROCKVILLE, Md., June 7, 2011 /PRNewswire/ — EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, today announced that Selected Value Therapeutics I, LLC (SVT) has exercised its right to acquire an exclusive license to develop and commercialize EntreMed’s Phase 2 oncology drug candidate, ENMD-2076, in China and certain of its territories. EntreMed retains development and commercialization rights to ENMD-2076 in the rest of the world.

(Logo: http://photos.prnewswire.com/prnh/20010620/ENMDLOGO )

The exercise is pursuant to an agreement between EntreMed and SVT dated as of September 7, 2010, which provided SVT with an option to acquire certain license, development and commercialization rights for ENMD-2076 in China and certain of its territories. The parties will begin negotiations of the license agreement, in accordance with the terms and conditions set forth in the 2010 agreement. Under the terms of the agreement, EntreMed is entitled to certain development milestone payments, as well as royalties on future product sales within the geographic market. SVT will be responsible for all clinical development and regulatory costs related to regulatory approval in the China territory.

John Xu, SVT President, commented, “We are pleased to be in a position to advance ENMD-2076 into clinical development in China. The data demonstrate the therapeutic activity of ENMD-2076 in a variety of indications and SVT is enthusiastic to be an integral part of the development of this exciting compound.”

Michael M. Tarnow, EntreMed’s Executive Chairman, commented on the transaction, “ENMD-2076 has shown activity in a number of cancers, most recently encouraging data from our Phase 2 study in ovarian cancer patients presented at the 2011 American Society of Clinical Oncology (ASCO) annual meeting. SVT’s option exercise is an important milestone for the ENMD-2076 program and for EntreMed. We are pleased with SVT’s commitment and confidence in ENMD-2076’s potential. We look forward to working with SVT as the development of ENMD-2076 progresses in China and we work to determine the design of future clinical trials.”

About ENMD-2076

ENMD-2076 is an orally-active, Aurora A/angiogenic kinase inhibitor with a unique kinase selectivity profile and multiple mechanisms of action. ENMD-2076 has been shown to inhibit a distinct profile of angiogenic tyrosine kinase targets in addition to the Aurora A kinase. Aurora kinases are key regulators of mitosis (cell division), and are often over-expressed in human cancers. ENMD-2076 also targets the VEGFR, Flt-3 and FGFR3 kinases which have been shown to play important roles in the pathology of several cancers. ENMD-2076 has shown promising activity in Phase I clinical trials in solid tumor cancers, leukemia, and multiple myeloma. ENMD-2076 is currently in a Phase 2 trial for ovarian cancer, and preclinical and clinical activities are ongoing in assessing the compound’s applicability for other forms of cancer.

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical company committed to developing ENMD-2076, a selective angiogenic kinase inhibitor, for the treatment of cancer. ENMD-2076 is currently in a multi-center Phase 2 study in ovarian cancer and in several Phase 1 studies in solid tumors, multiple myeloma, and leukemia. Additional information about EntreMed is available on the Company’s web site at www.entremed.com and in various filings with the Securities and Exchange Commission (the SEC).

Forward Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance, strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed.

Actual results could differ materially from those currently anticipated due to a number of factors, including: the risk that we may be unable to continue as a going concern as a result of our inability to raise sufficient capital for our operational needs; our reliance on a single product candidate, ENMD-2076; the volatility of our common stock; our history of losses and expectation of incurring continued losses; risks relating to the need for additional capital and the uncertainty of securing additional funding on favorable terms; the failure to consummate a transaction to monetize our Thalomid® royalty stream for any reason, including our inability to obtain the required third-party consents; our dependence on a royalty sharing agreement based on sales of a product, Thalomid®, that we do not have control; declines in actual sales of Thalomid® resulting in materially reduced royalty payments; risks associated with our product candidates; results in preclinical models that are not necessarily indicative of clinical results; uncertainties relating to preclinical and clinical trials, including delays to the commencement of such trials; any lack of progress of our research and development (including the results of our clinical trials); dependence on third parties; risks relating to the commercialization, if any, of our proposed products (such as marketing, safety, regulatory, patent, product liability, supply and other risks); and our ability to compete with larger, better financed biotechnology companies that may develop new approaches to the treatment of our targeted diseases. Additional information about the factors and risks that could affect our business, financial condition and results of operations, are contained in our filings with the SEC, which are available at www.sec.gov.

CONTACT:
Ginny Dunn
Associate Director, Corporate Communications & Investor Relations
EntreMed, Inc.
240.864.2643

Lannett (LCI) Announces Revised FDA PDUFA Date for Morphine Sulfate Oral Solution NDA

Jun. 6, 2011 (Business Wire) — Lannett Company, Inc. (NYSE AMEX: LCI) announced today that the U.S. Food and Drug Administration (FDA) has issued a revised Prescription Drug User Fee Act (PDUFA) goal date of June 23, 2011 for the company’s 505(b)(2) New Drug Application for Morphine Sulfate Oral Solution.

“With a revised PDUFA date in 17 days, we are preparing for the re-launch of our Morphine Sulfate Oral Solution product, if approved,” said Arthur Bedrosian, president and chief executive officer of Lannett.

About Lannett Company, Inc.:

Lannett Company, founded in 1942, develops, manufactures, packages, markets and distributes generic pharmaceutical products for a wide range of indications. For more information, visit the company’s website at www.lannett.com.

This news release contains certain statements of a forward-looking nature relating to future events or future business performance. Any such statements, including, but not limited to, the re-launch of Morphine Sulfate Oral Solution, whether expressed or implied, are subject to risks and uncertainties which can cause actual results to differ materially from those currently anticipated due to a number of factors which include, but are not limited to, the difficulty in predicting the timing or outcome of FDA or other regulatory approvals or actions, the ability to successfully commercialize products upon approval, Lannett’s estimated or anticipated future financial results, future inventory levels, future competition or pricing, future levels of operating expenses, product development efforts or performance, and other risk factors discussed in the company’s Form 10-K and other documents filed with the Securities and Exchange Commission from time to time. These forward-looking statements represent the company’s judgment as of the date of this news release. The company disclaims any intent or obligation to update these forward-looking statements.

PondelWilkinson Inc.

Robert Jaffe, 310-279-5980

Cover-All Technologies (COVR) Unveils Its New NexGen Business Intelligence Suite

Jun. 6, 2011 (Business Wire) — Cover-All Technologies Inc. (NYSE-Amex: COVR), a Delaware corporation, today at the annual IASA Conference announced the general availability of its NexGen Business Intelligence Suite, which can be leveraged either as an integrated component of My Insurance Center Business Acquisition Platform or as a stand-alone solution that can leverage data from virtually any insurance source system.

“We believe the NexGen Business Intelligence Suite is the industry’s most advanced and in-depth end-to-end solution,” described Manish Shah, President and CTO of the Company. “The NexGen Business Intelligence Suite provides data models for pre-staging, staging, warehouse and data mart covering core insurance subject areas, supporting global and diverse insurance business needs. Leveraging OLAP technology, the NexGen Business Intelligence Suite delivers hundreds of insurance metrics and slicing capabilities through various dimensions. Additionally, the included data flows between data models are developed based on several years of experience working with numerous source systems and their associated limitations. Emanating from our extensible and proven data model, the solution is designed to unify data from multiple business units, operating on multiple administrative platforms, into a consistent enterprise view of information for analysis and planning. With built-in performance management and analytics capabilities, which leverage secure user-configurable dashboards and scorecards, ours is truly a differentiated solution for insurance organizations.”

Mr. Shah added, “We already have a customer signed up to take advantage of these capabilities before the end of the second quarter.”

Cover-All architected the NexGen Business Intelligence Suite to be entirely turn-key, yet flexible enough to accommodate the nuances of each property & casualty insurance organization, in addition to being extensible for future business needs.

Shailesh Mehrotra, Vice President of Business Intelligence, explained, “The need for Business Intelligence capabilities is largely unchallenged in the insurance marketplace. The NexGen Business Intelligence Suite delivers on the promise of these capabilities by shortening the time and cost of implementation through our solution combined with our in-depth knowledge of the insurance processing complexities. Already serving a range of carriers, from large multinationals to smaller national players, our data model, ready-built ETL library, and comprehensive presentation layer can be fully operational in a three to six month timeframe – and even faster when integrated with My Insurance Center.”

“From our perspective, Business Intelligence initiatives for an organization should be strategically aligned with the business challenge,” continued Mr. Mehrotra. “Starting with a blank slate will risk the success of these initiatives very early on. Too often, these initiatives rush into delivery with only a limited understanding of the complexity of insurance data which places massive constraints on the extensibility of the solution. Further, these Business Intelligence systems are sometimes built for a specific user population and the accuracy of the information is often called into question. Ultimately, the business quite simply isn’t being served. A very attractive alternative is to leverage a turnkey solution which is the culmination of years of insurance experience, based on the latest information management practices, and most importantly, proven in the industry.”

“Today, more than ever before, insurance leaders need timely and accurate information to take advantage of opportunities and manage risk,” added John Roblin, Chairman and CEO. “Until now, the powerful capabilities of business intelligence technology have been elusive because of the complexities of property & casualty insurance and legacy systems. Cover-All developed our revolutionary NexGen Business Intelligence Suite to not only be powerful but also capable of delivering results in very short time frames. Over the last four years we have combined the latest technologies with a data-centric design and our deep understanding of insurance. Now, we are essentially a new company with industry leading technology and a rich solution set that is legacy code free and leverages the latest in Web 2.0 technology. Our NexGen Business Intelligence Suite is an exciting addition to our capabilities and is generating significant excitement with existing customers and prospects alike.”

About Cover-All Technologies Inc.

Cover-All Technologies Inc. is a leader in developing sophisticated software solutions for the property and casualty insurance industry. With our industry leading Business Acquisition Platform – My Insurance Center, and the recently announced Business Intelligence Solution Cover-All continues to expand its growing inventory of business focused, advanced technology solutions. The “New” Cover-all continues to innovate while leveraging its reputation for quality insurance solutions, knowledgeable people and outstanding customer service to enable our customers to achieve superior business results.

Pairing state-of-the-art functionality of My Insurance Center NexGen & the NexGen Business Intelligence Suite with experienced service professionals, who after implementation ensure continued compliance with statutory, regulatory, and market differentiation needs, Cover-All continues its tradition of innovating technology solutions to revolutionize the way the property and casualty insurance business is conducted.

Additional information is available online at www.cover-all.com.

Cover-All®, My Insurance Center™ (MIC) and Insurance Policy Database™ (IPD) are trademarks or registered trademarks of Cover-All Technologies Inc. All other company and product names mentioned are trademarks or registered trademarks of their respective holders.

Forward-looking Statements

Statements in this press release, other than statements of historical information, are forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks which may cause the Company’s actual results in future periods to differ materially from expected results. Those risks include, among others, risks associated with increased competition, customer decisions, the successful completion of continuing development of new products, the successful negotiations, execution and implementation of anticipated new software contracts, the successful addition of personnel in the marketing and technical areas, our ability to complete development and sell and license our products at prices which result in sufficient revenues to realize profits and other business factors beyond the Company’s control. Those and other risks are described in the Company’s filings with the Securities and Exchange Commission (“SEC”) over the last 12 months, including but not limited to the Company’s Annual Report on Form 10-K for the year ended December 31, 2010, filed with the SEC on March 24, 2011, and Post-Effective Amendment No. 1 to Form S-1 (File No. 333-156397) filed with the SEC on May 10, 2011, copies of which are available from the SEC or may be obtained upon request from the Company.

Cover-All:

Miguel A Edwards, 973-461-5211

SVP, Business Development

medwards@cover-all.com

or

Ann Massey, 973-461-5190

Chief Financial Officer

amassey@cover-all.com

or

Investor:

Hayden IR

Brett Maas, Principal, 646-536-7331

brett@haydenir.com

Raptor Pharmaceutical (RPTP) Provides Update on Phase 3 Clinical Trial of DR Cysteamine

NOVATO, Calif., June 6, 2011 (GLOBE NEWSWIRE) — Raptor Pharmaceutical Corp. (“Raptor” or the “Company”) (Nasdaq:RPTP), today announced that on June 3 the last clinical trial patient visits were completed and final data analysis will commence this week on the Phase 3 clinical trial of its delayed-release oral formulation of cysteamine bitartrate (“DR Cysteamine”) in patients with nephropathic cystinosis (“cystinosis”). The Company announced that 41 patients have completed the nine-week study protocol and the Company expects to report the data from this trial by the end of July 2011. The extension phase of the clinical trial, in which all patients completing the Phase 3 study may elect to continue on DR Cysteamine therapy, is ongoing.

The pivotal Phase 3 clinical trial is designed as an outpatient study of the safety, tolerability, pharmacokinetics (“PK”) and pharmacodynamics (“PD”) of every 12-hour DR Cysteamine compared to every 6-hour immediate-release cysteamine bitartrate in cystinosis patients. DR Cysteamine is designed for reduced dose frequency and improved tolerability, compared to immediate-release cysteamine, which is the current standard of care in cystinosis. The multi-center, randomized, crossover design of this comparative study is a result of discussions with the U.S. Food and Drug Administration (“FDA”) by which FDA provided significant guidance on trial protocol design, clinical endpoints, and statistical analyses.

“We are pleased to see our final patients complete the Phase 3 clinical trial and are gratified that 40 of the 41 patients completing the study have elected to enter our long-term extension study in which they have chosen to remain on the twice-a-day DR Cysteamine formulation,” commented Patrice Rioux M.D., Ph.D., CMO of Raptor. “As our earliest enrolled patients began to enter the extension study in August of last year, some patients have now been treated with DR Cysteamine for over 9 months; we currently have over 6 months of extension data on our first 20 patients.”

About Nephropathic Cystinosis

Nephropathic cystinosis is an inborn metabolic error characterized by the abnormal transport of cystine, an amino acid, out of the lysosomes. Poor compliance with current treatments for nephropathic cystinosis can cause serious health consequences, including renal failure and resultant need for a kidney transplant; growth failure; rickets and fractures; photophobia and blindness. Symptom onset typically occurs within the first year of life, when cystine crystals accumulate in various tissues and organs, including the kidneys, brain, liver, thyroid, pancreas, muscles and eyes.

About Cysteamine and DR Cysteamine

DR Cysteamine is Raptor’s proprietary enteric-coated, microbead oral formulation of cysteamine bitartrate designed to potentially reduce dosing frequency and reduce gastrointestinal side effects associated with immediate-release cysteamine bitartrate, which is approved for sale by the FDA and European Medicines Agency (“EMA”) to treat nephropathic cystinosis.

In December 2007, Raptor obtained an exclusive, worldwide license from the University of California, San Diego for the development DR Cysteamine for nephropathic cystinosis and cysteamine for other potential indications including Huntington’s Disease, NASH and Batten Disease.

About Raptor Pharmaceutical Corp.

Raptor Pharmaceutical Corp. (Nasdaq:RPTP) (“Raptor”) is dedicated to speeding the delivery of new treatment options to patients by working to improve existing therapeutics through the application of highly specialized drug targeting platforms and formulation expertise. Raptor focuses on underserved patient populations where it can have the greatest potential impact. Raptor currently has product candidates in clinical development designed to potentially treat nephropathic cystinosis, non-alcoholic steatohepatitis (“NASH”), Huntington’s Disease (“HD”), aldehyde dehydrogenase (“ALDH2”) deficiency, and thrombotic disorder.

Raptor’s preclinical programs are based upon bioengineered novel drug candidates and drug-targeting platforms derived from the human receptor-associated protein (“RAP”) and related proteins that are designed to target cancer, neurodegenerative disorders and infectious diseases.

For additional information, please visit www.raptorpharma.com.

The Raptor Pharmaceutical Corp. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=7180

FORWARD LOOKING STATEMENTS

This document contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements relate to future events or our future results of operation or future financial performance, including, but not limited to the following statements: that DR Cysteamine will reduce dose frequency and improve tolerability compared to immediate-release cysteamine; that final data review will occur and that the Company will report initial findings by the end of July, if at all; that all 40 patients will continue to participate in the Company’s long-term extension study in which patients remain on the twice-a-day DR Cysteamine formulation; and that Raptor will be able to successfully develop DR Cysteamine or any of its other product candidates. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, which may cause the Company’s actual results to be materially different from these forward-looking statements. Factors which may significantly change or prevent the Company’s forward looking statements from fruition include: that Raptor may be unsuccessful in developing any products or acquiring products; that Raptor’s technology may not be validated as it progresses further and its methods may not be accepted by the scientific community; that Raptor is unable to retain or attract key employees whose knowledge is essential to the development of its products; that unforeseen scientific difficulties develop with the Company’s process; that Raptor’s patents are not sufficient to protect essential aspects of its technology; that competitors may invent better technology; that Raptor’s products may not work as well as hoped or worse, that the Company’s products may harm recipients; and that Raptor may not be able to raise sufficient funds for development or working capital. As well, Raptor’s products may never develop into useful products and even if they do, they may not be approved for sale to the public. Raptor cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date they were made. Certain of these risks, uncertainties, and other factors are described in greater detail in the Company’s filings from time to time with the Securities and Exchange Commission (the “SEC”), which Raptor strongly urges you to read and consider, including: Raptor’s annual report on Form 10-K filed with the SEC on November 22, 2010; and Raptor’s quarterly report on Form 10-Q filed with the SEC on April 14, 2011; all of which are available free of charge on the SEC’s web site at http://www.sec.gov. Subsequent written and oral forward-looking statements attributable to Raptor or to persons acting on its behalf are expressly qualified in their entirety by the cautionary statements set forth in Raptor’s reports filed with the SEC. Raptor expressly disclaims any intent or obligation to update any forward-looking statements.

CONTACT: Trout Group (investors)
         Lauren Glaser
         (646) 378-2972
         lglaser@troutgroup.com

         The Ruth Group (media)
         Jason Rando
         (646) 536-7025
         jrando@theruthgroup.com

SCM Microsystems (INVE) Releases New NFC Reader Module for Commercial Application Developers

ISMANING, Germany, June 6, 2011 (GLOBE NEWSWIRE) — SCM Microsystems, a leading provider of solutions for secure access, secure identity and secure exchange and a business unit of Identive Group, Inc. (Nasdaq:INVE) (Frankfurt:INV), today announced its SCM3712 commercial NFC reader module, a compact add-on that enables NFC (Near Field Communication) peer-to-peer functionality for a wide range of devices and equipment, from handheld card readers to POS terminals to vending machines. The reader can be plugged into an existing commercial device to make it NFC ready and enable contactless, secure data exchange for applications such as cashless payments, ticketing, electronic ID and loyalty couponing. The SCM3712 NFC reader module is available now to OEMs and systems integrators.

“NFC technology is becoming increasingly important across a range of markets because it delivers the convenience of a “tap and go” user experience in a way that is highly secure,” said Michael Ganzera, Vice President Business Development and Marketing for SCM Microsystems. “System integrators are requesting NFC-enabling technology that is flexible and can be easily integrated into their equipment designs to accelerate time to market for new contactless products. The SCM3712 reader module from SCM Microsystems addresses this need with industry leading contactless technology that helps equipment suppliers participate fully in the emerging NFC eco-system.”

The SCM3712 NFC module has a small footprint, connects via a USB interface and is available with either an integrated antenna or an optional external antenna. It offers ISO 14443, FeliCa, NFC peer-to-peer functionality and is fully capable of handling NFC Forum-compliant tags based on MIFARE, FeliCa and Topaz technology as well as NFC-enabled mobile phones or other devices.

Upcoming NFC Software Development Kit

The SCM3712 NFC module will be included within SCM’s soon to be released NFC Software Development Kit (SDK) for application developers. The SDK will also include NFC Forum Tags as software, drivers and tools. SCM’s NFC Software Development Kit will be available in mid 2011.

About SCM Microsystems

SCM Microsystems, a business unit of Identive Group, Inc. (Nasdaq:INVE) (Frankfurt:INV), is a leading provider of solutions for secure access, secure identity and secure exchange. The company offers the world’s broadest range of contact, contactless and mobile smart card reader and terminal technology, digital identity and transaction platforms, as well as systems that integrate physical and logical access control. SCM’s smart card-based products and solutions are utilized around the world to enable security and identification applications, transaction systems, eHealth- and eGovernment programs and physical access systems. More information at www.scmmicro.com.

The SCM Microsystems logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=8073

Identive Group, Inc. is a leading provider of products, services and solutions for the security, identification and RFID industries. Additional information at www.identive-group.com.

Note: All trademarks are the property of their respective owners.

CONTACT: Annika Oelsner
         SCM Microsystems
         aoelsner@scmmicro.com
         +49 89 9595-5220

         Darby Dye
         Identive Group
         ddye@identive-group.com
         +1 949 553-4251

ADA-ES (ADES) Announces $60 Million Equity Sale in Clean Coal Solutions, LLC Joint Venture

Jun. 6, 2011 (Business Wire) — ADA-ES, Inc. (NASDAQ:ADES) (“ADA”) today announced the sale of a 15.8% equity interest in Clean Coal Solutions, LLC (“Clean Coal”), ADA’s 50:50 joint venture with an affiliate of NexGen Resources Corporation (“NexGen”), by ADA and NexGen for $60 million to GSFS Investments I Corp. (“GSFS”), an affiliate of The Goldman Sachs Group, Inc. (“Goldman Sachs”). Closing of the transaction was simultaneous with signing.

GSFS’s 15.8% equity interest in Clean Coal is represented by Class B Units, which are non-voting except as to approval rights on certain matters. The Class B Units entitle the holder to a targeted return of at least 15%. ADA and NexGen each received gross proceeds of $30 million at closing and ADA will receive an additional $1.8 million payment from NexGen to maintain NexGen’s interest in Clean Coal. Given the 2.5% direct interest both ADA and NexGen retain in the individual entities previously formed to lease the “Refined Coal” facilities, the effective sharing ratio of net cash generated by all expected Refined Coal operations is 15% to GSFS and 85% to ADA and NexGen.

Clean Coal’s patented coal technology, CyClean, is a cost effective coal technology to produce Refined Coal, which reduces emissions of NOx and mercury. The American Jobs Creation Act of 2004 included changes to Section 45 of the Internal Revenue Code that incentivize the production of Refined Coal through an annually escalating tax credit, which is presently $6.33 per ton.

In conjunction with the equity purchase, Clean Coal granted Goldman Sachs the exclusive right to lease Refined Coal facilities targeted to produce up to 12 million tons of Refined Coal per year on terms that will be economically more favorable to Clean Coal than those in effect for the leases that Clean Coal entered into with another affiliate of Goldman Sachs in June 2010.

Dr. Michael D. Durham, President and CEO of ADA, commented, “We are very pleased to welcome this additional investment by Goldman Sachs. We believe that their continued financial interest in Clean Coal further validates the environmental and financial benefits of this proven emissions control technology. As we continue to assess ADA’s liabilities resulting from the arbitration panel’s recent interim award to Norit Americas, Inc. and related indemnity obligations, this cash infusion enhances our balance sheet and our ability to fulfill those obligations.”

Additional information regarding the transaction is available in ADA’s Current Report on Form 8-K, which ADA filed with the United States Securities and Exchange Commission on June 3, 2011.

About ADA-ES

ADA-ES is a leader in clean coal technology and the associated specialty chemicals, serving the coal-fueled power plant industry. Our proprietary environmental technologies and specialty chemicals enable power plants to enhance existing air pollution control equipment, minimize mercury, CO₂ and other emissions, maximize capacity, and improve operating efficiencies, to meet the challenges of existing and pending emission control regulations.

With respect to mercury emissions:

• We supply activated carbon (“AC”) injection systems, mercury measurement instrumentation, and related services.
• We are also a joint venture participant in ADA Carbon Solutions (“ADA-CS”), which has commenced operations at its AC production facility
• Under an exclusive development and licensing agreement with Arch Coal, we are developing and commercializing an enhanced Powder River Basin (“PRB”) coal with reduced emissions of mercury and other metals.
• Through our consolidated subsidiary, Clean Coal Solutions, LLC (“Clean Coal”), we provide our patented Refined Coal technology, CyClean, to enhance combustion of and reduce emissions from burning PRB coals in cyclone boilers.

In addition, we are developing CO₂ emissions technologies under projects funded by the U.S. Department of Energy (“DOE”) and industry participants.

ADA-ES, Inc.

Michael D. Durham, Ph.D., MBA, President, 303-734-1727

Mark H. McKinnies, Senior VP & CFO, 303-734-1727

www.adaes.com

or

Investor Relations Counsel

The Equity Group Inc.

www.theequitygroup.com

Melissa Dixon, 212-836-9613

MDixon@equityny.com

or

Devin Sullivan, 212-836-9608

DSullivan@equityny.com

FluoroPharma Medical (FPMI) Enters Public Equity Markets via Reverse Merger; Raises $3.5 Million in Capital

In a reverse merger, Commercial E Waste Management (formerly traded under ticker symbol CEWM) recently acquired FluoroPharma Medical, a developer of proprietary PET imaging products. The newly formed company is now known as FluoroPharma Medical. Upon finalizing the transaction, FluoroPharma Medical completed a capital raising effort through the placement of $3.5 million in stock.

Thijs Spoor, FluoroPharma’s CEO, commented the following, “This merger and capital infusion provide FluoroPharma with the resources to advance the clinical development of our promising PET imaging agents for acute and chronic coronary disease and novel Alzheimer preclinical tracers.”

The inventor of FluoroPharma’s imaging technology, Dr. David Elmaleh, who’s also board chair for the new company, noted that the enterprise had already translated “scientific insights into data from clinical trials in two separate cardiac imaging indications and now look forward to taking the next steps in the development of these agents.”

PET (Positron Emission Tomography) uses gamma ray pairs to produce a three-dimensional image of the body’s functional processes. Tracers, or positron-emitting radionuclides, are introduced on biologically active molecules to facilitate the process, typically by injection. PET scans are usually read together with MRI and CT scans. The FluoroPharma approach, in cardiac medicine, targets the heart’s myocardial cells or coronary arterial plaques.

The company’s ambitious plans to provide similar diagnostics for Alzheimer’s disease could be of great benefit to patients and their clinicians, since early diagnosis is increasingly viewed as important to successful treatment and slowing the disease’s progress. At least one other company – Avid RadioPharmaceuticals – is also in the field, but has had some problems which might be relieved by advanced computer analysis of PET results.

However, despite Avid’s issues with its Alzheimer’s imaging agent florbetapir, it was deemed promising enough by Eli Lilly Pharmaceutical (NYSE: LLY) to result in Lilly’s acquisition of Avid last November in a stunning $300-million deal, with an additional $500 million on the backend based on regulatory approvals. FluoroPharma, which has already had Phase I successes with its cardiac PET agents, was thus a very logical takeover candidate.

Alzheimer’s disease is a disease of the brain in which certain beta amyloid proteins form tangled plaques which interfere with neurologic signals. The chemistry of these plaques was identified in the 1990s by Dr. Changiz Geula and others at Boston’s Beth Deaconess Hospital and Harvard Medical School. In a related development in the late 1980s, Dr. Stanley Prusiner, who later was awarded a Nobel Prize for his work, established the existence of an entirely new class of pathogens, prions, a type of protein – as precursors of diseases similar to Alzheimer’s, though to date scientists have been reluctant to link prions to Alzheimer’s.

The FluoroPharma website says that the company has four U.S. patents and seven pending patent applications, “in addition to strong international protection.” It also actively seeks acquisition of other PET technologies from “from individuals and institutions.” The company has established close research affiliations with Harvard Medical School and Massachusetts General Hospital. With leading technologies and historic deals such as the Lilly/Avid acquisition behind it, FlouroPharma could very quickly capture the attention of the investment community.

Let us hear your thoughts below:

Breeze-Eastern (BZC) Reports Record Fiscal 2011 and Fourth Quarter Results

Jun. 3, 2011 (Business Wire) — Breeze-Eastern Corporation (NYSE Amex: BZC) today reported its Fiscal 2011 financial results.

• Net sales: $78.2 million, a company record high, versus $69.0 million for Fiscal 2010.
• Net income: $5.0 million, or $0.53 per diluted share, versus a net loss of ($6.0) million, or ($0.64) per diluted share, last year.
• Adjusted EBITDA, a “Non-GAAP Financial Measure” as described below in this press release: $11.9 million, versus a negative ($4.3) million in Fiscal 2010.
• Net debt: $5.1 million, $9.6 million lower than a year ago.
• Bookings: $79.2 million, versus $68.2 million in Fiscal 2010. The book-to-bill ratio for Fiscal 2011 was 1.0.

Even after excluding unusual non-recurring costs from Fiscal 2010, Fiscal 2011 profits were significantly better than last year Fiscal 2010 results included non-cash charges in the fourth quarter of $12.2 million for inventory obsolescence, environmental liabilities, and estimated losses on engineering project commitments, and also included $1.5 million of one-time costs related to the factory shutdown during the relocation in March, 2010. Excluding these amounts, adjusted Fiscal 2010 net income would have been $2.3 million, or $0.25 per diluted share, and Adjusted EBITDA would have been $9.5 million. Fiscal 2011 net income was more than double the adjusted Fiscal 2010 net income and Adjusted EBITDA was up more than 25%.

For the Fiscal 2011 fourth quarter, the financial results follow.

• Net sales: $26.9 million, a company record high, versus $18.1 million in last year’s Fiscal fourth quarter.
• Net income: $2.8 million, or $0.30 per diluted share, versus a loss of ($8.9) million, or ($0.95) per diluted share, in the Fiscal 2010 fourth quarter.
• Adjusted EBITDA: $5.8 million, versus a negative ($11.5) million in the Fiscal 2010 fourth quarter.
• Bookings: $25.3 million, versus $21.7 million in the Fiscal 2010 fourth quarter.

Mike Harlan, Chief Executive Officer and President, said, “Our Fiscal 2011 and fourth quarter sales set new company records. We are proud of this accomplishment and the extra effort by many of our employees to achieve these records. Our bookings were much higher than last year, benefiting from higher spare parts orders from the U.S. Government. Our overall profitability was clearly better than the prior year, but was impacted by our relocation and other factors and still has room for improvement. I regard our Fiscal 2011 income statement results as a good step toward the level of performance we expect to deliver.

“Our balance sheet and cash flow continue to be strong. In addition to a good increase in Adjusted EBITDA, a broad team effort increased working capital turnover, which resulted in over $11 million in operating cash flow. We used this strong cash flow to make four debt principal pre-payments, while still funding significant new product development and completion of our relocation to Whippany. Our debt net of cash was $5.1 million at the end of Fiscal 2011 versus $14.7 million a year ago. When our debt was over $60 million, it was an overriding issue for our company; but after extensive efforts, our balance sheet is now a strategic asset. I am also glad to report that after recent evaluations, we believe our environmental reserves are still appropriate and we are not making any adjustments.

“Looking ahead to Fiscal 2012, first quarter shipments are doing well and we are on-track to make significant milestone deliveries for the C-27J, CH-53K, and A400M programs this summer. We will continue to invest in new product development, IT improvements, and improved customer responsiveness during Fiscal 2012, and still improve our net profitability.”

The Company will conduct a conference call at 10:00 a.m. EDT on Friday, June 3, 2011 with the following numbers: (800) 798-2796 or (617) 614-6204 and passcode 19374578.

Breeze-Eastern Corporation (http://www.breeze-eastern.com) is the world’s leading designer and manufacturer of high performance lifting and pulling devices for military and civilian aircraft, including rescue hoists, winches and cargo hooks, and weapons-lifting systems. The Company employs approximately 160 people at its facilities in Whippany, New Jersey.

Non–GAAP Financial Measures

In addition to disclosing financial results that are determined in accordance with Generally Accepted Accounting Principles (“GAAP”), the Company also discloses Adjusted EBITDA (earnings before interest, taxes, depreciation and amortization, other income/expense, loss on debt extinguishment, and relocation expense). The Company presents Adjusted EBITDA because it considers it an important supplemental measure of performance. Measures similar to Adjusted EBITDA are widely used by the Company and by others in the Company’s industry to evaluate performance and valuation. The Company believes Adjusted EBITDA facilitates operating performance comparisons from period to period and company to company by backing out potential differences caused by variations in capital structure (affecting relative interest expense), tax positions (such as the impact on periods or companies of changes in effective tax rates or net operating losses) and the age and book depreciation of facilities and equipment (affecting relative depreciation expense). The Company also presents Adjusted EBITDA because it believes it is frequently used by investors and other interested parties as a basis for evaluating performance.

Adjusted EBITDA has limitations as an analytical tool, and should not be considered in isolation or as a substitute for analysis of the Company’s results as reported under GAAP. Some of the limitations of Adjusted EBITDA are that (i) it does not reflect the Company’s cash expenditures for capital assets, (ii) it does not reflect the significant interest expense or cash requirements necessary to service interest or principal payments on the Company’s debt, and (iii) it does not reflect changes in, or cash requirements for, the Company’s working capital. Furthermore, other companies in the aerospace and defense industry may calculate these measures differently than the manner presented above. Accordingly, the Company focuses primarily on its GAAP results and uses Adjusted EBITDA only supplementally. A reconciliation of Adjusted EBITDA to net income, the most directly comparable GAAP measure, for the three and twelve months ended March 31, 2011 is shown in the tables below.

INFORMATION ABOUT FORWARD-LOOKING STATEMENTS

This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, regarding our future operating performance, financial results, events, trends and plans. All statements in this news release other than statements of historical facts are forward-looking statements. Forward-looking statements involve numerous risks and uncertainties. We have attempted to identify any forward-looking statements by using words such as “anticipates,” “believes,” “could,” “expects,” “intends,” “may,” “should” and other similar expressions. Although we believe that the expectations reflected in all of our forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct. Such statements are not guarantees of future performance or events and are subject to known and unknown risks and uncertainties that could cause our actual results, events or financial positions to differ materially from those included within the forward-looking statements. Such factors include, but are not limited to competition from other companies; changes in applicable laws, rules, and regulations affecting the Company in the locations in which it conducts its business; interest rate trends; a decrease in the United States government defense spending, changes in spending allocation or the termination, postponement, or failure to fund one or more significant contracts by the United States government or other customers; changes in our sales strategy and product development plans; changes in the marketplace; developments in environmental proceedings that we are involved in; continued services of our executive management team; status of labor relations; competitive pricing pressures; market acceptance of our products under development; delays in the development of products; determination by us to dispose of or acquire additional assets; general industry and economic conditions; events impacting the U.S. and world financial markets and economies; and those specific risks disclosed in our Annual Report on Form 10-K for the fiscal year ended March 31, 2011, and other filings with the Securities and Exchange Commission. We undertake no obligation to update publicly any forward-looking statements, whether as a result of new information or future events.

Breeze-Eastern Corporation

Mike Harlan, 973-602-1001

CEO, President, and Director

Tianyin Pharmaceutical Co., Inc. (TPI) Board Reinstates Stock Repurchase Program

Tesla Motors, Inc. (TSLA) Announces Pricing of Its Follow-On Offering

PALO ALTO, CA — (Marketwire) — 06/03/11 — Tesla Motors, Inc. (NASDAQ: TSLA), a manufacturer of high-performance fully electric vehicles and advanced electric vehicle powertrain components, announced today that it has priced and fully allocated its follow-on offering of 5,300,000 shares of common stock at a price to the public of $28.76 per share, the closing price for Tesla shares on June 2, 2011. The closing price of Tesla’s common stock on May 24, 2011, the day before Tesla announced the offering, was $26.72 per share. In addition, Tesla has granted the underwriter a 30-day option to purchase up to an additional 795,000 shares of common stock. All shares are being offered by Tesla.

Additionally, in a private placement to occur concurrently with the closing of the public offering, Elon Musk, Tesla’s Chief Executive Officer and cofounder, plans to purchase 1,416,000 shares of common stock directly from Tesla at the public offering price and Blackstar Investco LLC, an affiliate of Daimler AG, plans to purchase up to 637,475 shares of common stock directly from Tesla at the public offering price.

Tesla intends to use a portion of the net proceeds from this offering and the concurrent private placement to fund the development of its Model X crossover vehicle.

Goldman, Sachs & Co. acted as Sole Underwriter for the public offering.

A registration statement relating to the securities was declared effective by the Securities and Exchange Commission on June 2, 2011. Any offer or sale will be made only by means of a written prospectus forming part of the effective registration statement. Copies of the final prospectus relating to the offering may be obtained from Goldman, Sachs & Co., via telephone: (866) 471-2526; facsimile: (212) 902-9316; email: prospectus-ny@ny.email.gs.com; or standard mail: Goldman, Sachs & Co., Attn: Prospectus Department, 200 West Street, New York, NY 10282-2198.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Add to Digg Bookmark with del.icio.us Add to Newsvine

GT Solar (SOLR) Receives $460.4 Million Order for Advanced Sapphire Crystallization Furnaces

Jun. 3, 2011 (Business Wire) — GT Solar International, Inc. (NASDAQ: SOLR), a global provider of polysilicon production technology, and sapphire and silicon crystalline growth systems and materials for the solar, LED and other specialty markets, today announced that it has received an order for its advanced sapphire crystallization furnaces totaling $460.4 million from a new market entrant. The order is GT’s largest single order to date, and represents a significant milestone for the company as a leader in the fast-growing LED industry. The order will be included in GT’s backlog for its current Q1 FY12, which ends on July 2, 2011.

“Our customer is a well established, diversified manufacturing company located in China who is new to the LED industry. We are pleased that they have selected our advanced sapphire growth technology for their new sapphire production facility,” said Tom Gutierrez, GT Solar’s president and CEO. “The market acceptance of our sapphire growth technology has been remarkable and it speaks to the confidence our customers have shown in our ability to help them build successful businesses that leverage our crystalline growth expertise and our global equipment installation and support resources.”

According to Strategies Unlimited, an industry analyst firm that tracks the LED industry, revenue for high brightness LED applications will be approximately $19 billion by 2015, with general lighting applications accounting for about 25 percent of this total. High brightness LEDs are primarily manufactured on sapphire wafers. This growth is driving the expansion of manufacturing capacity to meet the increased demand for high quality sapphire material.

About GT Solar International, Inc.

GT Solar International, Inc. is a global provider of polysilicon production technology, and sapphire and silicon crystalline growth systems and materials for the solar, LED and other specialty markets. The company’s products and services allow its customers to optimize their manufacturing environments and lower their cost of ownership. GT Solar will be changing its name to GT Advanced Technologies as it establishes a new global brand. The new name reflects the broader range of markets and technologies the company now addresses since its acquisition of Crystal Systems in July of 2010. The transition to GT Advanced Technologies is expected to be completed in August 2011. For additional information about GT Solar, please visit www.gtsolar.com.

Forward-Looking Statements

Some of the statements in this press release are forward-looking in nature, including statements regarding expected revenue from customer contracts and the expected performance of the sapphire furnaces. These statements are based on management’s current expectations or beliefs. These forward-looking statements are not a guarantee of performance and are subject to a number of uncertainties and other factors, many of which are outside the Company’s control, which could cause actual events to differ materially from those expressed or implied by the statements. Factors that may cause actual events to differ materially from those expressed or implied by our forward-looking statements include the possibility that the Company is unable to recognize revenue on customer contracts, that technological changes could render existing products or technologies obsolete, the Company may be unable to protect its intellectual property rights, competition from other manufacturers may increase, exchange rate fluctuations and conditions in the credit markets and economy may reduce demand for the Company’s products and various other risks as outlined in GT Solar International, Inc.’s filings with the Securities and Exchange Commission, including the statements under the heading “Risk Factors” in the Company’s annual report on Form 10-K for fiscal 2011 filed on May 26, 2011, and the quarterly report on Form 10-Q for the third quarter of fiscal 2011 filed on February 10, 2011. GT Solar International, Inc. is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events, or otherwise.

Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=6747633&lang=en

GT Solar

Media

Jeff Nestel-Patt, 603-204-2883

jeff.nestelpatt@gtsolar.com

or

Investors/Analysts

Ryan Blair, 603-681-3869

ryan.blair@gtsolar.com

American Woodmark Corporation (AMWD) Announces Fourth Quarter Results and Declares Quarterly Dividend

DGSE (DGSE) Announces the Grand Opening of its First Two DGSE Bullion Express Locations

New Gold (NGD) Closes Acquisition of Richfield

    <<
    -   A large gold asset in British Columbia where New Gold has significant
        experience through the continued development of its New Afton Project

    -   Immediate 22% increase to New Gold's gold resources through
        Blackwater's initial mineral resource estimate

    -   Significant exploration potential above and beyond current resource
        base - deposit open in all directions and at depth

    -   Compliments New Gold's already robust growth pipeline with an
        exciting gold asset

    -   Ability to fund exploration and development from internal cash flow

    -   Leverage off of teams that brought Cerro San Pedro and Mesquite open
        pit mines into production as well as team developing New Afton in
        British Columbia

    -   Potential to become New Gold's largest gold producing asset

    -   Tax synergies with New Afton

    -   Minimal shareholder dilution of approximately 10%
    >>

    <<
    -------------------------------------------------------------------------
                          Indicated                     Inferred
    -------------------------------------------------------------------------
                            Grade                         Grade
                         ----------- Contained         ----------- Contained
                 Tonnes  Gold Silver      Gold Tonnes  Gold Silver      Gold
    Property     (000's) (g/t)  (g/t)    (Moz) (000's) (g/t)  (g/t)    (Moz)
    -------------------------------------------------------------------------
    Total
     Blackwater  53,460  1.06    5.6      1.83 75,452  0.96    4.0      2.34
    -------------------------------------------------------------------------
    Dave and
     Jarrit
     (100% New
     Gold)       53,128  1.07    5.6      1.82 29,183  1.04    5.5      0.98
    -------------------------------------------------------------------------
    Davidson
     (75% New
     Gold, 25%
     Silver
     Quest
     Resources
     Ltd.)          331  0.92    5.0      0.01 46,269  0.92    3.1      1.36
    -------------------------------------------------------------------------
    Total New
     Gold        53,377  1.06    5.6      1.83 63,885  0.97    4.2      2.00
    -------------------------------------------------------------------------
    >>

    <<
    -------------------------------------------------------------------------
    About New Gold Inc.

    New Gold is an intermediate gold mining company. The company has a
    portfolio of three producing assets and three significant development
    projects. The Mesquite Mine in the United States, the Cerro San Pedro
    Mine in Mexico and Peak Gold Mines in Australia are expected to produce
    between 380,000 and 400,000 ounces of gold in 2011. The fully-funded New
    Afton project in Canada is scheduled to add further growth in 2012. In
    addition, New Gold owns 30% of the world-class El Morro project located
    in Chile and, in June 2011, New Gold acquired the exciting Blackwater
    project in Canada. For further information on the company, please visit
    www.newgold.com.
    -------------------------------------------------------------------------
    >>

Orexigen® Therapeutics (OREX) Schedules June 3, 2011 Webcast and Conference Call

Telvent (TLVT) Announces Agreement for Acquisition by Schneider Electric

ROCKVILLE, Md., June 1, 2011 (GLOBE NEWSWIRE) — Telvent GIT, S.A. (Nasdaq:TLVT), a leading real-time IT solutions and information provider for a sustainable world, announced today that Telvent and Schneider Electric have entered into an agreement under which Schneider Electric will launch an offer to acquire all Telvent shares at U.S. $40.00 per share. In connection with the transaction, Abengoa has irrevocably agreed to tender its 40% stake in Telvent to Schneider Electric in the offer. The transactions are subject to certain conditions, including approvals of European and U.S. competition authorities and other material conditions.

Schneider Electric expects to launch its tender offer by mid-June 2011 and to close the transaction in the third quarter. The transaction has been approved by the board of directors of Telvent, which formed a special committee to review the transaction on behalf of the public shareholders of Telvent.

Ignacio González Domínguez, Telvent’s Chairman and CEO, said: “We see strong complementarities of Telvent’s solution offering and that of Schneider Electric, as well as a good cultural fit of people and spirit. We believe that our customers will benefit highly from this combination. With Schneider Electric, Telvent expects to expand its global footprint, especially in the fast growing new economies. We look forward to this next phase of the development of our company.”

Important Notice

The planned tender offer described in this communication has not yet commenced. This communication is not an offer to buy or the solicitation of an offer to sell securities. At the time the planned tender offer is commenced, Schneider Electric will file a tender offer statement on Schedule TO with the Securities and Exchange Commission (the “SEC”), and Telvent will file a solicitation/recommendation statement on Schedule 14D-9 with respect to the planned tender offer. The tender offer statement (including an offer to purchase, a related letter of transmittal and other tender offer documents) and the solicitation/recommendation statement will contain important information that should be read carefully before making any decision to tender securities in the planned tender offer. Those materials will be made available to Telvent’s stockholders at no expense to them. In addition, all of those materials (and all other tender offer documents filed with the SEC) will be made available at no charge on the SEC’s website: www.sec.gov.

About Telvent

Telvent (Nasdaq:TLVT) is a global IT solutions and business information services provider dedicated to helping improve efficiency, safety and security for the world’s leading companies. Telvent serves markets that are critical to the sustainability of the planet, including the energy, transportation, agricultural and environmental sectors. (www.telvent.com)

The Telvent GIT S.A. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=6852

Forward Looking Statements:

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements often are proceeded by words such as “believes,” “expects,” “may,” “anticipates,” “plans,” “intends,” “assumes,” “will” or similar expressions. Forward-looking statements reflect management’s current expectations, as of the date of this press release, and involve certain risks and uncertainties. Actual results and events could differ materially from those anticipated in these forward-looking statements as a result of various factors. Those factors include the performance by the parties of their obligations under the agreements entered into with respect to the tender offer and Abengoa’s sale of its Telvent shares, the approval of the transaction by European and U.S. competition authorities and the satisfaction of the other conditions to the consummation of the transactions.

Telvent does not intend, and does not assume any obligation, to update or revise the forward-looking statements in this document after the date it is issued. In light of the risks and uncertainties described above, and the potential for variation of actual events from the assumptions on which certain of such forward-looking statements are based, investors should keep in mind that the results, events or developments disclosed in any forward-looking statement made in this document may not occur, and that actual events may vary materially from those described herein, including those described as anticipated, expected, targeted, projected or otherwise.

CONTACT: Investor Relations Contact

         Manuel Fernandez Maza
         Tel. +1 301 354 5432
         Email: ir@telvent.com

         Communications Department Contact

         Patricia Malo de Molina
         Tel. +34 954 93 71 11
         Email: comunicacion@telvent.com

Westinghouse Solar (WEST) to Introduce AC Solar Power System at Intersolar Europe

CAMPBELL, Calif., June 1, 2011 (GLOBE NEWSWIRE) — Westinghouse Solar, Inc. (Nasdaq:WEST), a designer and manufacturer of solar power systems, announced that it will be exhibiting at booth number A3-220 during the upcoming Intersolar 2011 trade show on June 8-10, 2011 in Munich, Germany. Westinghouse Solar will exhibit their latest Plug-and-Play AC module as well as their DC system for commercial systems.

“We are excited to be unveiling the industry’s first fully integrated AC solar panel into Europe, the world’s largest solar market,” said Barry Cinnamon, CEO of Westinghouse Solar. “Panel prices have declined to the point at which direct and indirect labor expenses are now the largest single component of system costs. With integrated racking, wiring and grounding, Westinghouse Solar Power Systems eliminate 80% of the field assembly components and save 50% of the labor compared to ordinary solar power systems, thereby providing greater margin opportunity to rooftop system installers.”

Westinghouse Solar’s 235 watt AC panel features a second-generation integrated frame, as well as features that enhance the panel’s reliability and ease of installation. For commercial rooftops, Westinghouse Solar will be showing its lightweight, non-penetrating flat roof solar power system that is also based on a large-format 235 watt panel. Westinghouse Solar currently sells its integrated solar panels to a 300-strong network of dealers and installers in North America. The company’s new 235 watt AC and DC panels are expected to begin shipping to customers this summer at attractive price points.

Parties interested in additional information or to meet with the company at this event should contact Gary Mull at 408.402.9478 or gmull@westinghousesolar.com.

About Westinghouse Solar: (Nasdaq:WEST)

Westinghouse Solar is a designer and manufacturer of solar power systems. In 2007, Westinghouse Solar pioneered the concept of integrating the racking, wiring and grounding directly into the solar panel. This revolutionary solar panel, originally branded “Andalay”, quickly won industry acclaim. In 2009, the company again broke new ground with the first integrated AC solar panel, reducing the number of components for a rooftop solar installation by approximately 80 percent and lowering labor costs by approximately 50 percent. This first AC panel, which won the 2009 Popular Mechanics Breakthrough Award, has become the industry’s most widely installed AC solar panel. Award-winning Westinghouse Solar Power Systems provide the best combination of safety, performance and reliability, while backed by the proven quality of the Westinghouse name. For more information on Westinghouse Solar, visit www.westinghousesolar.com.

The Westinghouse Solar logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=7801

WEST-G

CONTACT: Public Relations Contact:
         Sara Blood
         Carmichael Lynch Spong
         (612) 375-8504
         sara.blood@clynch.com

Marvell Technology (MRVL) to Present at Upcoming Investor Conferences

SANTA CLARA, Calif., May 27, 2011 /PRNewswire/ — Marvell Technology Group Ltd. (NASDAQ:MRVL – News), a global leader in integrated silicon solutions, will be presenting at the following investor conferences:

• Bank of America Merrill Lynch Technology Conference in New York City on June 1, 2011
• NASDAQ OMX Investor Program in London on June 21, 2011

(Logo: http://photos.prnewswire.com/prnh/20100719/SF36559LOGO-b)

The conferences noted above will be audio webcast and can be accessed at the Marvell Investor Relations website at http://investor.marvell.com/.

About Marvell

Marvell is a global leader in the development of storage, communications and consumer silicon solutions. Marvell’s diverse product portfolio includes switching, transceiver, communications controller, wireless, and storage solutions that power the entire communications infrastructure, including enterprise, metro, home, and storage networking. As used in this release, the term “Marvell” refers to Marvell Technology Group Ltd. and its subsidiaries. For more information please visit www.marvell.com.

Marvell^® and the Marvell logo are registered trademarks of Marvell and/or its affiliates.

China’s Booming Agriculture Sector Benefits Yongye (YONG) and AgFeed (FEED)

NEW YORK, NY–(Marketwire – 05/27/11) – Agriculture represents one of the most important sectors of China’s economy, providing more than 12 percent of the country’s total Gross Domestic Product and employing in excess of 300 million farmers. China’s growing agricultural sector has not only boosted profits for farmers, but has also benefitted Chinese producers of agricultural chemicals and animal feed. The Bedford Report examines China’s Agricultural Sector and provides research reports on Yongye International, Inc. (NASDAQ:YONG – News) and AgFeed Industries, Inc. (NASDAQ:FEED – News). Access to the full company reports can be found at:

www.bedfordreport.com/2011-05-YONG

www.bedfordreport.com/2011-05-FEED

Yongye International is a leading agricultural nutrient company headquartered in Beijing, with its production facilities located in Hohhot, Inner Mongolia, China. The company produces and markets two lines of organic nutrient products: a liquid nutrient product which is sprayed on plants and a powder nutrient product which is added to animal feed. Earlier this month the company said that first quarter revenues more than doubled year-on-year due to an expanded distribution network, deeper penetration in existing market and the significantly enhanced market recognition of its products.

The Bedford Report releases regular market updates on China’s Agricultural Sector so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.bedfordreport.com and get exclusive access to our numerous analyst reports and industry newsletters.

AgFeed Industries operates two businesses in the People’s Republic of China: animal feed nutrition and hog production. Revenues for the company’s US hog production unit reached $57.9 million with an operating profit of $3.6 million. In its Chinese based animal nutrition segment, the Company reports first quarter revenue of $24.2 million and an operating loss of $835,000.

The Bedford Report provides Analyst Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. The Bedford Report has not been compensated by any of the above mentioned publicly traded companies. The Bedford Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks.

NASDAQ Welcomes Leading Renewable Oil Company Solazyme (SZYM)

NEW YORK, May 27, 2011 (GLOBE NEWSWIRE) — The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ – News) today announced that trading of Solazyme, a renewable oil company and leader in industrial biotechnology, commenced on The NASDAQ Stock Market on Friday, May 27, 2011. Solazyme is listed under the ticker symbol (Nasdaq:SZYM – News) and is one of the most highly anticipated renewable oil IPOs of the year.

“NASDAQ OMX is a pioneer in the clean energy sector, as evidenced by our comprehensive family of indexes covering the global green economy (https://indexes.nasdaqomx.com/green.aspx),” said Bruce Aust, Executive Vice President and head of the NASDAQ OMX Corporate Client Group. “Solazyme exemplifies the type of innovative and forward-thinking companies that thrive on our exchange. We are thrilled to welcome them to The NASDAQ Stock Market and look forward to watching their continued growth and success in the future.”

Solazyme is a renewable oil company and a leader in industrial biotechnology. Founded in 2003 and headquartered in South San Francisco, Solazyme’s proprietary technology is dedicated to transforming a range of low-cost plant-based sugars into high-value oils. Solazyme’s oils and fuels provide compelling solutions to increasingly complex issues of fuel scarcity, energy security and environmental impact while fitting into the pre-existing infrastructure.

NASDAQ OMX is the exchange of choice for the clean energy community and 72% of the companies included in the NASDAQ Clean Edge Green Energy Index (CELS) list on The NASDAQ Stock Market. In addition to CELS, NASDAQ OMX offers the investment community nearly 70 Green Economy Indexes, which help companies, investors and policymakers understand and profit from clean technologies.

About NASDAQ OMX

The NASDAQ OMX Group, Inc. is the world’s largest exchange company. It delivers trading, exchange technology and public company services across six continents, with more than 3,500 listed companies. NASDAQ OMX offers multiple capital raising solutions to companies around the globe, including its U.S. listings market, NASDAQ OMX Nordic, NASDAQ OMX Baltic, NASDAQ OMX First North, and the U.S. 144A sector. The company offers trading across multiple asset classes including equities, derivatives, debt, commodities, structured products and exchange-traded funds. NASDAQ OMX technology supports the operations of over 70 exchanges, clearing organizations and central securities depositories in more than 50 countries. NASDAQ OMX Nordic and NASDAQ OMX Baltic are not legal entities but describe the common offering from NASDAQ OMX exchanges in Helsinki, Copenhagen, Stockholm, Iceland, Tallinn, Riga, and Vilnius. For more information about NASDAQ OMX, visit http://www.nasdaqomx.com. *Please follow NASDAQ OMX on Facebook (http://www.facebook.com/pages/NASDAQ-OMX/108167527653) and Twitter (http://www.twitter.com/nasdaqomx).

iBio (IBIO) Announces Successful Production of Critical Hookworm Vaccine Antigen

May 26, 2011 (Business Wire) — iBio, Inc. (NYSE AMEX: IBIO) today announced that its proprietary iBioLaunch™ Platform successfully expressed the hookworm-derived molecule known as NaAPR1M-74, which will be evaluated as a potential vaccine candidate for human hookworm disease.

The expression of this antigen represents a major breakthrough in the development of a human hookworm vaccine. Such a vaccine will provide significant public health benefit by preventing a parasitic disease that currently affects more than 576 million people worldwide and is a leading cause of anemia in the world’s poorest countries. This accomplishment highlights the ability of iBioLaunch technology to overcome inherent limitations of other expression systems.

The success resulted from collaboration between iBio’s research partner, the Fraunhofer Center for Molecular Biotechnology (FCMB), and the Sabin Vaccine Institute. Production of initial quantities of partially purified NaAPR1M-74 was completed last week at FCMB’s pilot manufacturing facility employing the iBioLaunch Technology. This product was later transferred to Walter Reed Army Institute for Research (WRAIR) for final purification to formulate enough material to initiate Phase 1 clinical trials.

“We are very pleased with the success in expressing a pilot batch of this antigen in collaboration with iBio and FCMB,” said Dr. Peter Hotez, President of Sabin Vaccine Institute. “It has been extremely difficult to produce this protein effectively, as evidenced by multiple prior unsuccessful attempts using traditional production systems.”

“The expression of this complex protein with the iBioLaunch™ Platform not only moves us closer to a solution for hundreds of millions of people who suffer from hookworm, but also bodes well for other complex protein expression challenges,” said Dr. Philip Russell, a member of the Board of Trustees of Sabin Vaccine Institute and member of the Board of Directors of iBio.

Clinical trials will be conducted by the Sabin Vaccine Institute’s Human Hookworm Vaccine Initiative (HHVI). Established in 2000 with funding from the Bill & Melinda Gates Foundation and with additional support from the Dutch Ministry of Foreign Affairs and the Brazilian Ministry of Health, the HHVI is the first and only program that aims to reduce the prevalence of human hookworm infection through research and development, timely dissemination of results, innovation, and advocacy.

About iBio, Inc.

iBio, Inc. is a biotechnology company offering its proprietary, transformative iBioLaunch technology platform for the production of biologics including therapeutic proteins and vaccines. The iBioLaunch platform uses transient gene expression in green plants for superior efficiency in protein production. Advantages include significantly lower capital and process costs, and the technology is ideally suited for complex proteins and for applications where speed, scalability, and surge capacity are important. The iBioLaunch technology was developed for iBio by the not-for-profit Fraunhofer USA Center for Molecular Biotechnology (FCMB) during the past eight years to overcome the inadequacies of existing technologies. iBio granted a fully paid-up, non-exclusive, non-commercial license to the iBioLaunch Technology solely for the purpose of developing, manufacturing and distributing hookworm vaccine for Global Access Objectives – the Bill & Melinda Gates Foundation program to provide vaccines for the people most in need within developing countries of the world – reserving a right of first refusal to provide each of technology transfer and/or manufacturing services required to achieve the Global Access objectives on a commercially reasonable, competitive and sustainable cost basis. iBio owns the intellectual property and technology developed at FCMB, and continues to sponsor development and application of the technology for biological applications in human health. Further information is available at www.ibioinc.com.

About Fraunhofer USA Center for Molecular Biotechnology

Fraunhofer USA CMB, a division of Fraunhofer USA, Inc., is a not-for-profit research organization whose mission is to develop safe and effective vaccines targeting infectious diseases and autoimmune disorders. The technology CMB developed for iBio, Inc. provides a safe, rapid and economical alternative for both vaccine and therapeutic protein production. The Center conducts research in the area of plant biotechnology, utilizing new, cutting edge technologies applicable to the diagnosis, prevention and treatment of human and animal diseases. The Center houses individuals with expertise and excellence in plant virology, pathology, molecular biology, immunology, vaccinology, protein engineering, and biochemistry. Further information is available at www.fraunhofer-cmb.org.

About Sabin Vaccine Institute

Sabin Vaccine Institute is a non-profit, 501(c) (3) organization of scientists, researchers, and advocates dedicated to reducing needless human suffering caused by vaccine preventable and neglected tropical diseases. Sabin works with governments, leading public and private organizations, and academic institutions to provide solutions for some of the world’s most pervasive health care challenges. Since its founding in 1993 in honor of the oral polio vaccine developer, Dr. Albert B. Sabin, the Institute has been at the forefront of efforts to control, treat, and eliminate vaccine preventable and neglected tropical diseases by developing new vaccines, advocating use of existing vaccines, and promoting increased access to affordable medical treatments. For more information, please visit www.sabin.org.

Forward-Looking Statements

Statements included in this news release related to iBio, Inc. may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as competitive factors, technological development, market demand, and the Company’s ability to obtain new contracts and accurately estimate net revenues due to variability in size, scope and duration of projects. Further information on potential risk factors that could affect the Company’s financial results can be found in the company’s Reports filed with the Securities and Exchange Commission.

iBio, Inc.

Corporate:

Robert Erwin, 302-355-2335

President

rerwin@ibioinc.com

or

Investors:

Laurie Roop, 302-355-9452

ir@ibioinc.com

Zoom Technologies (ZOOM) Regains Compliance With NASDAQ

BEIJING, May 26, 2011 (GLOBE NEWSWIRE) — Zoom Technologies, Inc. (Nasdaq:ZOOM) (or the “Company”), a leading China based manufacturer of mobile phones and related products, today reported that Nasdaq Listing Qualifications has notified the Company via a letter dated May 23, 2011 that the Company has regained compliance with Rule 5635(c) and, upon the disclosure of the matter which the Company completed by the filing of a Form 8-K on May 25, 2011, the matter is now closed.

The NASDAQ Stock Market brought to the Company’s attention on April 1, 2011 that the Company had not been in compliance with NASDAQ Rule 5635(c), which generally requires shareholder approval of equity-based compensation plans. On December 10, 2009, the Company adopted its 2009 Equity Incentive Compensation Plan (the “Plan”) without obtaining shareholder approval.

The Company promptly filed a Definitive Information Statement on Form 14C on April 4, 2011, thereby evidencing shareholder approval for the Plan. Accordingly, NASDAQ has determined that the Company has regained compliance with Rule 5635(c).

The Company has not received a notice of delisting from NASDAQ.

About Zoom Technologies

Zoom Technologies is a holding Company with subsidiaries that engage in the manufacturing, research and development, and sale of electronic and telecommunication products for the latest generation mobile phones, wireless communication circuitry and related software products. Zoom Technologies’ subsidiary, Jiangsu Leimone, owns a majority stake of TCB Digital, which offers highly customized and high quality Electronic Manufacturing Service (EMS) for Original Equipment Manufacturer (OEM) customers as well as its Own Brand Manufacturing (OBM) under the Zoom and Leimone brand names. The Company’s products are both exported and sold domestically in People’s Republic of China.

The Zoom Technologies, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=9665

CONTACT: Investor Contact:
         Tina Xiao
         Investor Relations Manager
         Zoom Technologies, Inc.
         +1 917-609-0333
         tinaxiao@zoom.com
         www.zoom.com

Special Committee of Fushi Copperweld, Inc. (FSIN) Provides Update Regarding “Going Private” Proposal

Syms Corp (SYMS) Initiates Process to Explore and Evaluate Various Potential Strategic Alternatives

Merriman Capital’s (MERR) Clean Energy Semiconductors Analyst Receives StarMine Analyst Award

Ramtron (RMTR) Ships First F-RAM Samples Built on New IBM Manufacturing Line

May 25, 2011 (Business Wire) — Ramtron International Corporation (Nasdaq: RMTR), a leading developer and supplier of ferroelectric-based low-power memory and integrated semiconductor products, today announced broad sampling of the first pre-qualification ferroelectric random access memory (F-RAM) devices built on the company’s new manufacturing line at IBM Corporation (NYSE: IBM). The FM24C04C and FM24C16C are serial 5-volt devices with 4- and 16-kilobits of F-RAM memory, respectively. The devices offer a high-performance nonvolatile data collection and storage solution for electronic systems. Ramtron’s F-RAM products provide nonvolatile RAM memory performance with NoDelay™ writes, high read/write endurance, and low power consumption.

“Releasing samples of the FM24C04C and FM24C16C devices is a significant milestone in our new foundry program,” said Eric Balzer, Ramtron’s CEO. “These pre-qualification devices, which meet all datasheet specifications and our stringent quality standards, are available now for customer evaluation. Additional devices, including 3-volt I2C and 3- and 5-volt SPI products, will become available for sampling as testing is completed.”

The FM24C04C and FM24C16C feature a serial I2C interface, have an active current of 100µA (typical at 100kHz) and perform up to 1MHz bus frequency. The devices are direct drop-in replacements for 4- and 16-Kb serial EEPROM memories used in industrial controls, metering, medical, military, gaming, and computing applications, among others. The FM24C04C and FM24C16C are offered in an industry standard 8-pin SOIC package and operate over the industrial temperature range of -40°C to +85°C.

Ramtron’s FM24CxxC products offer single-byte writes that are 200 times faster than those of EEPROM. In addition, the devices offer no timing delays and can be written to at standard bus speeds as compared to EEPROM, which requires a 5- to 10-millisecond write delay before new data can be registered. The FM24C04C and FM24C16C feature 1-trillion write cycles, compared to 1-million write cycles for EEPROM, and have an extremely low operating current compared to competing nonvolatile memory products.

About the IBM/Ramtron Foundry Relationship

Ramtron and IBM entered into a foundry services agreement in early 2009 that called for the installation of Ramtron’s F-RAM semiconductor process technology in IBM’s Burlington, Vermont, advanced wafer manufacturing facility. Ramtron’s proprietary F-RAM technology stack has been inserted into IBM’s 0.18 micron CMOS process to create Ramtron’s signature high-performance nonvolatile F-RAM products. IBM’s world-class foundry provides a flexible and cost effective manufacturing platform for Ramtron’s existing products and new product development initiatives.

About Ramtron and F-RAM Technology

Ramtron International Corporation, headquartered in Colorado Springs, Colorado, is a fabless semiconductor company that designs, develops and markets specialized semiconductor memory and integrated semiconductor solutions used in a wide range of product applications and markets worldwide.

Ramtron pioneered the integration of ferroelectric materials into semiconductor products, which enabled the development of a new class of nonvolatile memory, called ferroelectric random access memory, or F-RAM. Ramtron’s ferroelectric memories combine the high speed of DRAM (Dynamic Random Access Memory) with nonvolatile data storage, or the ability to save data without power. Since commercializing the technology, Ramtron has sold nearly a half-billion F-RAM devices into demanding applications such as automotive safety and entertainment systems, portable medical devices, industrial process control systems, smart electricity meters, and consumer printer cartridges. As the most power-efficient of any nonvolatile memory technology on the market, F-RAM products promise to pave the way for the development of ultra-efficient battery powered products and energy harvesting applications, among others. For more information, visit www.ramtron.com.

Safe Harbor Statement

“Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995: Statements herein that are not historical facts are “forward-looking statements.” These forward-looking statements involve risks, uncertainties and assumptions that could cause actual outcomes and results to differ materially from those indicated by these forward-looking statements. Please refer to Ramtron’s Securities and Exchange Commission filings for a discussion of such risks. The forward-looking statements in this report are being made as of the date of this report, and Ramtron expressly disclaims any obligation to update or revise any forward-looking statements contained herein.

Ramtron International Corporation

PR:

Christopher Wray, 719-481-7182

chris.wray@ramtron.com

or

IR:

Lee A. Brown, 719-481-7213

lee.brown@ramtron.com

Zogenix (ZGNX) Stockholders Elect Mark Wiggins to Board of Directors

SAN DIEGO, May 25, 2011 (GLOBE NEWSWIRE) — Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, announced today that the Company’s stockholders have elected Mark Wiggins as a new member of the Company’s Board of Directors. Zogenix’s stockholders also re-elected Cam L. Garner and Louis C. Bock to the Board. Mr. Wiggins will also serve as a member of the Compensation Committee of the Board.

Mr. Wiggins brings over 25 years of product commercialization and business development experience to the Zogenix Board. Mr. Wiggins currently serves as the Chief Business Officer of Mpex Pharmaceuticals overseeing strategic business operations of the company. Prior to Mpex, Mr. Wiggins served as Executive Vice President, Corporate and Business Development of Biogen Idec, Inc. In this position, he was responsible for worldwide partnering, licensing and corporate acquisitions. Prior to Biogen’s merger with Idec Pharmaceuticals in 2003, Mr. Wiggins was the Vice President of Marketing and Business Development at Idec, serving on the management committee for the collaboration with Genentech on Rituxan^®. Mr. Wiggins received his B.S. degree in Finance from Syracuse University and an M.B.A. from the University of Arizona.

Cam L. Garner, Chairman of the Board, said, “We are pleased to welcome Mark to the Zogenix Board of Directors. He has an ideal mix of experience in product commercialization and business development that will be valuable as we continue to drive adoption of SUMAVEL DosePro, prepare for commercialization of ZX002, and look for partnership opportunities that leverage our patented DosePro delivery system. We expect that Mark will provide valuable strategic contributions as a Board member and I look forward to working with him as we continue to grow Zogenix’s business.”

In addition to Mpex and Biogen Idec, Mr. Wiggins’ 25 years of pharmaceutical and biotechnology industry experience includes senior positions at Pfizer, Johnson & Johnson’s Ortho Pharmaceutical, Schering Plough and Hybridon. Throughout his career he held progressively senior positions across the commercialization spectrum, covering marketing, reimbursement, licensing, acquisitions, and collaborations.

Mr. Wiggins commented, “I am excited to join Zogenix at this key stage in its development. The Company has several commercial avenues for growth and an established drug delivery platform technology. I look forward to working with the Board and management to maximize the Company’s potential.”

About Zogenix

Zogenix, Inc. (Nasdaq:ZGNX), with offices in San Diego and Emeryville, California, is a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain. Zogenix’s first commercial product, SUMAVEL^® DosePro^® (sumatriptan injection) Needle-free Delivery System, was launched in January 2010 for the acute treatment of migraine and cluster headache. Zogenix’s lead product candidate, ZX002, is a novel, oral, single-entity controlled-release formulation of hydrocodone currently in Phase 3 clinical trials for the treatment of moderate to severe chronic pain in patients requiring around-the-clock opioid therapy.

Forward Looking Statements

Zogenix cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as “believes,” “anticipates,” “plans,” “expects,” “indicates,” “will,” “intends,” “potential,” “suggests,” “assuming,” “designed” and similar expressions are intended to identify forward-looking statements. These statements are based on the company’s current beliefs and expectations. These forward-looking statements include statements regarding the adoption of SUMAVEL DosePro and the growth of Zogenix’s business. The inclusion of forward-looking statements should not be regarded as a representation by Zogenix that any of its plans will be achieved. Actual results may differ from those set forth in this presentation due to the risk and uncertainties inherent in Zogenix’s business, including, without limitation: the market potential for migraine treatments, and Zogenix’s ability to compete within that market; inadequate therapeutic efficacy or unexpected adverse side effects relating to SUMAVEL DosePro that could prevent its ongoing commercialization, or that could result in recalls or product liability claims; Zogenix’s dependence on its collaboration with Astellas Pharma US, Inc. to promote SUMAVEL DosePro; the ability of Zogenix to ensure adequate and continued supply of SUMAVEL DosePro to successfully meet anticipated market demand; the ability of Zogenix and its licensors to obtain, maintain and successfully enforce adequate patent and other intellectual property protection of its products and product candidates and the ability to operate its business without infringing the intellectual property rights of others; and other risks described in Zogenix’s filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Zogenix undertakes no obligation to revise or update this presentation to reflect events or circumstances after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.

For additional information, please visit www.zogenix.com.

RITUXAN is a trademark of Biogen Idec.

SUMAVEL (R) and DosePro (R) are registered trademarks of Zogenix, Inc.

CONTACT: INVESTORS:
         Zack Kubow | The Ruth Group
         646.536.7020 | zkubow@theruthgroup.com

         MEDIA:
         Jason Rando | The Ruth Group
         646.536.7025 | jrando@theruthgroup.com